Opinion|Videos|February 13, 2026
Exploring Targeted Strategies in Early-Stage EGFR+ NSCLC
Subcutaneous amivantamab offers significant advantages over IV administration, including reduced infusion reactions and quicker patient turnover in clinics.
Advertisement
Episodes in this series
Joshua K. Sabari, MD, and Alexander I. Spira, MD, PhD, FACP, FASCO, turn to the evolving role of targeted therapy in earlier-stage EGFR-mutated NSCLC. They outline ongoing research evaluating EGFR-directed approaches in the adjuvant and perioperative settings. The discussion highlights how these strategies may shift treatment paradigms beyond metastatic disease.
Advertisement
Related to this article
David VanderWeele, MD, PhD, reviews where lutetium Lu 177 vipivotide tetraxetan fits across metastatic prostate cancer, how to select and manage patients, and the new radionuclides, targeting molecules, and antigens under investigation.
Longer follow-up of CAPItello-281 showed capivasertib plus abiraterone extended survival in PTEN-deficient hormone-sensitive prostate cancer.
Joshua J. Meeks, MD, PhD, explains how enfortumab vedotin plus pembrolizumab is reshaping organ preservation in MIBC.
Katie S. Murray, DO, discusses how efficacy, toxicity, patient preferences, and treatment logistics guide BCG-unresponsive NMIBC care.
Vignesh T. Packiam, MD, reviews why improved BCG outcomes support its first-line use, with gemcitabine/docetaxel as a BCG-sparing option.
Experts break down key gastrointestinal cancer data and trends from the 2026 ESMO Congress.
Experts break down key melanoma data and trends from the 2026 ESMO Congress.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Amivantamab and Hyaluronidase for Metastatic HNSCC
2
BCG Optimization Becomes a Priority as Durvalumab Gains a Role in High-Risk NMIBC
3
Dr Skoulidis on Divarasib vs Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
4
Zanidatamab, CLDN18.2-Directed ADCs, Ivonescimab, and KRAS Inhibitor Data Headline Key GI Cancer Findings From ESMO 2026
5